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Doxycycline hinders phenylalanine 
fibril assemblies revealing a 
potential novel therapeutic 
approach in phenylketonuria
Ada De Luigi1, Alessandro Mariani2, Massimiliano De Paola2, Andrea Re Depaolini2, 
Laura Colombo1, Luca Russo1, Valeria Rondelli3, Paola Brocca3, Lihi Adler-Abramovich4,5, 
Ehud Gazit4, Elena Del Favero3, Laura Cantù3 & Mario Salmona1
A new paradigm for the aetiopathology of phenylketonuria suggests the presence of amyloid-
like assemblies in the brains of transgenic mouse models and patients with phenylketonuria, 
possibly shedding light on the selective cognitive deficit associated with this disease. Paralleling 
the amyloidogenic route that identifies different stages of peptide aggregation, corresponding 
to different levels of toxicity, we experimentally address for the first time, the physico-chemical 
properties of phenylalanine aggregates via Small Angle, Wide Angle X-ray Scattering and Atomic 
Force Microscopy. Results are consistent with the presence of well-structured, aligned fibres 
generated by milliMolar concentrations of phenylalanine. Moreover, the amyloid-modulating 
doxycycline agent affects the local structure of phenylalanine aggregates, preventing the formation 
of well-ordered crystalline structures. Phenylalanine assemblies prove toxic in vitro to immortalized 
cell lines and primary neuronal cells. Furthermore, these assemblies also cause dendritic sprouting 
alterations and synaptic protein impairment in neurons. Doxycycline counteracts these toxic effects, 
suggesting an approach for the development of future innovative non-dietary preventive therapies.
Mutations in the phenylalanine hydroxylase (PAH) gene cause the partial or total inhibition of enzyme 
activity1. An excess of phenylalanine (Phe), resulting from failure in the biotransformation to tyrosine, 
is at the basis of the onset and progression of phenylketonuria (PKU)2. PAH is expressed not only in the 
liver but also in the kidneys, pancreas and brain3, and deficiency in the conversion of Phe may be mild 
(in the case of hyperphenylalaninemia (HPA)) or moderate to severe (in the case of PKU) in association 
with poorly tolerated (360–600 μ mol/L) or toxic (> 600 μ mol/L) plasma levels in a free diet condition. 
High and persistent levels of Phe are teratogenic during foetal development (microcephaly, congenital 
heart defects), and continue after birth if a controlled diet is not followed. Notably, in the 1950s it was 
demonstrated that high levels of blood Phe also cause neuropsychological deficiencies4. Pharmacological 
intervention as a non-dietary alternative to prevent or mitigate the cognitive deficit associated with 
PKU is increasingly desirable. The development of a therapeutic strategy extending to all PKU patients 
requires an understanding of the molecular basis of the deficit progression, i.e., the mechanism of the 
disease. The connection between metabolite accumulation and neuronal cell malfunction is still unclear, 
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even though several mechanisms have been proposed to explain the neuropathological findings observed 
in PKU. Recently, a new paradigm has been put forward to explain the aetiopathology of PKU5. Attention 
has been drawn to the features of the Phe precipitate that forms above the solubility limit. Long uniaxial 
aggregates, indicated as amyloid-like structures, have been observed in aqueous solutions both in vitro 
and in transgenic mice and PKU patients. These have been proven to display cytotoxicity that can be 
neutralized by specific antibodies. Although quite different from the typical amyloid fibres, nonetheless 
this finding is suggestive of a novel approach to the molecular basis of PKU, addressing the possible role 
of Phe aggregates in the disease, interfering with the cellular functions. The propensity to form fibrils 
depends on the concentration of Phe in the milliMolar range that promotes a tight packing of the aro-
matic ring in ordered structures (hydrophobic π -π stacking interaction)6,7. The fibrillar morphology, as 
defined by the characteristic birefringence under cross-polarization, has also been confirmed by light 
scattering, thioflavin T and ANS binding assays8. It has been suggested that aromatic interaction plays a 
crucial role in creating an ordered configuration and energetic contribution in the molecular assembly 
of amyloid structures. Notably, in amyloidogenic peptides the substitution of the aromatic amino acid is 
crucial to the fibrillation process; therefore, the study of the self-assembly of Phe fibrils offers the oppor-
tunity to discover antibodies or small molecules for a novel therapeutic approach9.
In this paper, paralleling the amyloidogenic route that identifies different stages of peptide aggrega-
tion, corresponding to different levels of toxicity, we experimentally address the physico-chemical prop-
erties of Phe aggregates before confirming that anti-Phe assembly antibodies counteract their toxicity, as 
determined in primary neuronal cells and immortalized cells. This strategy was pursued to unequivocally 
determine that Phe assemblies are not only supermolecular structures, but also have a biological activity 
that can be a target for pharmacological therapy.
In the light of these observations, in an attempt to identify a novel pharmacological approach for PKU10 
we have focused our attention on doxycycline (Doxy) for its capacity to hinder amyloidogenic peptides 
and protein aggregation, destabilize protein aggregates and promote their degradation by proteases11–14.
In the last fifteen years, following our first report showing that tetracyclines inhibited the aggrega-
tion of prion protein fragments and Alzheimer’s β peptides, a large amount of research has showed 
that tetracyclines inhibit the aggregation of transthyretin, W7FW14F apomyoglobin, amylin, hunting-
tin, α -synuclein, alpha-macroglobulin, polyadenylate binding nuclear protein 1 and immunoglobulin 
light-chain15–17. The blood brain barrier passage of Doxy was recently confirmed in patients suffer-
ing from Creutzfeldt-Jakob disease, since its concentrations could be determined in autopsy samples 
treated with 100 mg Doxy daily. Levels ranging between 646–3,051 ng/g of brain tissue were measured 
in individuals who received the last dose within 24 h of death16. The use of Doxy as an orphan drug for 
the treatment of systemic amyloidosis caused by mutated transthyretin (Treatment of familial amyloid 
polyneuropathy. EU/3/12/955) and of β 2-microglobulin amyloidosis (Treatment of systemic amyloido-
sis caused by β 2-microglobulin. EU/3/12/961) was recently approved by the European Committee for 
Orphan Medicinal Products. Tetracyclines are involved in more than 130 clinical trials, unrelated to their 
antimicrobial activity18.
Results
Small angle X-ray scattering on deposited phenylalanine aggregates. X-ray scattering exper-
iments were performed to obtain structural information about the supramolecular organization of Phe 
aggregates and reveal the effect of the presence of Doxy on their structure. Solutions, at a final concen-
tration of 20 mM in ddH2O, were prepared and left to dry on a thin kapton support in the presence of 
a 7T magnetic field. This procedure has been already applied to induce macroscopic alignment of fibers 
of small amyloidogenic peptides during slow evaporation of aqueous solvent19,20.
Figure 1 shows the 2D images, in the SAXS and WAXS regions (top and bottom rows, respectively), 
collected for pure Phe and mixed Phe:Doxy (1:0.005 and 1:0.05 molar ratios, simultaneously dissolved). 
The SAXS intensity patterns are very different. The Phe scattered pattern (top row, left panel) is typical 
for long fibres aligned in the direction of the vertical axis. The macroscopic organization of fibres is not 
determined by the applied external magnetic field, as different regions of the sample show different orien-
tations. Alignment instead seems to be governed by dewetting and dehydration; however, in each region, 
it extends on a length scale comparable to the X-ray beam cross size (0.3 × 0.2 mM). Even at a low molar 
ratio, the presence of Doxy dramatically affects the SAXS diffraction pattern (Phe:Doxy = 1:0.005), as vis-
ible in Fig. 1 (top row, centre panel). A long-range supramolecular organization of Phe after dehydration 
is still observable, giving rise to the small-angle scattered intensity, but alignment of fibres is strongly 
reduced. For higher Doxy content (Phe:Doxy = 1:0.05; top row, right panel), the SAXS pattern is almost 
isotropic and the total scattered intensity is lower, as for less structured systems.
On the other hand, X-ray scattering experiments in the WAXS region allow the investigation of the 
supramolecular organization of the different systems at a local scale (< 1 nm). The intensity patterns are 
reported in Fig. 1, bottom row. In the case of pure Phe (left panel), intensity maxima are arcs centred on 
meridional or equatorial axes, thus pertaining to along or across organization with respect to the elonga-
tion / alignment axis of the aggregated structures. The regrouped Phe spectrum, with the angular posi-
tion of all peaks, is reported in the Supplementary Information (Figure S1). Results are consistent with 
the presence of well-structured, aligned fibres. Our findings are in good agreement with recent results 
obtained by molecular dynamics simulation studies6 and X-ray crystallography7. We observe equatorial 
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peaks in the 5Å-range, consistent with the proposed repetition distance of piled Phe rings, while a lead-
ing peak is seen on the 15Å-range distances, consistent with the proposed lateral organization of Phe 
strings in a thicker fibre. Besides differences in the details of local arrangement, twofold or fourfold 
structures at the molecular level, both previous studies identify hydrogen bonding and π -π stacking as 
the dominant short range interactions that scale up to give rise to axially ordered aggregates. Our results 
show that the presence of Doxy affects the local structure of Phe aggregates, preventing the formation 
of well-ordered crystalline structures, as shown in Fig. 1 (right panel). In particular, as evidenced in the 
Supplementary Information, the presence of small amounts of Doxy hinders the lateral organization, 
as indicated by an important depletion of the corresponding order peak (at q = 4.4 nm−1) and by the 
inversion of the relative weight of the meridional and equatorial peaks intensities. This suggests that, at 
this Doxy content, individual Phe piling up is still preserved at the expense of the lateral organization of 
Phe strings, maybe enhancing their chimeric behaviour. At higher Doxy content structuring is hindered 
at all lenghtscales.
Atomic force microscopy of phenylalanine assemblies: interference of doxycycline. AFM 
studies were carried out to clarify the morphology of Phe assemblies prepared in different solvents with 
different pH and salt conditions, in the absence or in the presence of Doxy.
Figure 2 shows images relative to 1 mM Phe (left column) and Phe:Doxy (1:0.005) (right column) in 
ddH2O. It can easily be seen that the aggregative behaviour of the two systems is completely different, 
the one containing Doxy being populated by smaller aggregated structures. In the case of the pure Phe 
sample, a broad distribution of species is seen, ranging from 2 to 12 nm in height (Fig. 2A) and from 10 
to 290 nm in diameter (Fig.  2B), with two major populations in the 50–90 nm (31%) and 100–220 nm 
(41%) ranges (Fig. 2B). The co-incubation with Doxy (1:0.005 molar ratio) had a remarkable influence 
on the height and diameter of the observed species (Fig. 2D,E). In particular, 98% of them were under 
5 nm in height (Fig. 2G) and under 100 nm in diameter (Fig. 2H).
The same effect of Doxy in hindering Phe aggregation has been observed at different pH values, 
namely pH 4.7 and pH 9.2, as reported in Figures S2 and S3 of the Supporting Information.
In order to mimic the experimental conditions of studies carried out on primary neurons and immor-
talized cell lines and check the effect of the presence of salt, AFM measurements were also performed in 
10 mM PBS, pH 7.4. Figure 3 shows images relative to 1 mM Phe (left column) and Phe:Doxy (1:0.005) 
(right column) in PBS. Again, the aggregative behaviour of the two systems is completely different, the 
one containing Doxy being populated by smaller aggregated structures. In the case of the pure Phe sam-
ple, a broad distribution of species is observed, ranging from 10 to 30 nm in height (Fig. 3C) and from 
25 to 100 nm in diameter (Fig. 3D). The co-incubation with Doxy (1:0.005 molar ratio) had a remarkable 
influence on the size of the observed species (Fig. 3E–H), with 98% under 1 nm in height (Fig. 3G) and 
65% under 15 nm in diameter (Fig. 3H).
Phenylalanine assemblies as a target for pharmacological therapy. Before carrying out in vitro 
toxicity tests on immortalized and primary neuronal cells, we tested the cytotoxicity of Phe assemblies 
alone and confirmed that antibodies raised against them could hinder or counteract this effect. To this 
Figure 1. X-ray scattering 2D patterns for pure 20 mM Phe (left column) and mixed Phe:Doxy, 1:0.005 
(central column) and 1:0.05 molar ratios (right column). Solutions were prepared in ddH2O and allowed 
to dry on a thin Kapton support. Images show SAXS (top row) and WAXS (bottom row) patterns.
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end, 20 mM Phe were dissolved in culture medium, anti-Phe antibody preparation was added to the 
culture medium to immunoprecipitate the aggregates and cell toxicity studies were carried out. As a 
supplementary approach to remove Phe assemblies, a separate batch of the medium was also incubated 
with Sepharose-Protein A beads to deplete all immunoglobulins present in the medium. HeLa cells 
treated with a solution containing 20 mM Phe assemblies showed 65.7 ± 3.5% viability; after immuno-
precipitation the viability of cells was increased to 88.3 ± 3.7%, determined via MTT assay. Moreover, 
the total depletion of the immune complex from the culture medium using Sepharose-Protein A beads 
increased cell viability to 81.5 ± 4.9%, confirming the selectivity of the antibody against Phe assemblies 
(Fig. 4A). As supplementary controls, we also tested the effect on cell viability (in brackets) of: i) 20 mM 
Figure 2. Tapping mode atomic force microscopy images (amplitude data). Images (Panels (A,B) refer to 
pure Phe and co-dissolved Phe:Doxy at 1:0.005 molar ratio (E,F), freshly prepared in ddH2O. Diameters and 
heights were determined by SPIP analysis. Panels (C,D,G,H) show the frequency distribution of the different 
assemblies obtained for the two systems. The scale bars correspond to an amplitude range of − 25/ + 25 mV 
for panels (A,E) and − 10/ + 10 mV for panels (B,F).
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Phe assemblies incubated with Sepharose-Protein A beads alone (71.7 ± 3.2%), ii) control rabbit IgG 
(66 ± 9.5%), iii) Sepharose-Protein A beads alone in the absence of Phe (108 ± 15.8%) and iv) anti-Phe 
antibody alone (93.5 ± 11.9%).
Incubation with Sepharose-Protein A beads and anti-Phe antibody were used as negative controls for 
Phe effects in hippocampal mixed cultures, as described above for HeLa cells. The reduction of neuronal 
viability by 20 mM Phe (49.7 ± 14.9%) was also significantly increased to 74.9 ± 8.2% in the presence of 
anti-Phe antibody (p < 0.001 vs Phe). No effects of Sepharose-Protein A beads incubation alone were 
observed (Fig. 4B).
Figure 3. Tapping mode atomic force microscopy images (amplitude data). Images (Panels (A,B) refer to 
pure Phe and co-dissolved Phe:Doxy at 1:0.005 molar ratio (E,F), freshly prepared in PBS (10 mM, pH 7.4). 
Diameters and heights were determined by SPIP analysis. Panels (C,D,G,H) show the frequency distribution 
of the different assemblies obtained for the two systems. The scale bars correspond to an amplitude range of 
− 25/ + 25 mV for panels (A,E) and − 10/ + 10 mV for panels (B,F).
www.nature.com/scientificreports/
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Toxicity of phenylalanine assemblies on SH-SY5Y and HeLa cell lines. In neuronal and 
non-neuronal human cell lines the growth inhibition after high concentration of Phe was dose-dependent 
(Fig. 5A,B). The SH-SY5Y cell line showed a statistically significant reduction in viability starting from 
6 mM Phe, after 24 h of treatment (− 17.2%; 95% CI 6.498 to 27.84) that was more pronounced at 12 and 
24 mM (− 31% and − 52%; 95% CI 19.83 to 41.17 and 41.66 to 63.00, respectively). HeLa cell viability 
was affected by the treatment at 12 mM of Phe (− 28%; 95% CI 9.301 to 46.37) and became more pro-
nounced at 24 mM (− 57%; 95% CI 38.63 to 75.70). Similar EC50 values were obtained for both cell lines 
(SH-SY5Y 22.6 mM, 95% CI 19.2 to 26.6 mM; HeLa 20.5 mM, 95% CI 16.6 to 25.3 mM). The incubation 
of both cell lines with 12 mM Ala (used as a negative control) for 24 h did not influence cell viability 
(SH-SY5Y 101 ± 16%; HeLa 102 ± 7.5%).
Reversal of phenylalanine assemblies toxicity by doxycycline. After establishing the most 
appropriate experimental conditions, we tested whether doxycycline could reduce Phe assembly tox-
icity. Three Phe:Doxy molar ratios were used in all experiments: 20 mM:100 μ M, 20 mM:50 μ M and 
20 mM:25 μ M. In the SH-SY5Y cell line (Fig.  6A), Doxy was effective down to 50 μ M, increasing cell 
viability from 58 ± 4.3% to 70 ± 6.1%. A similar increase was observed with 100 μ M (71 ± 5.4%). In the 
HeLa cell line (Fig. 6B), Doxy was effective at 25 μ M and 50 μ M, increasing viability from 61 ± 13.7% to 
78 ± 9.0% and 80 ± 13.7%, respectively. As a negative control we used the antibiotic gentamicin, which 
is structurally unrelated to Doxy. Under our experimental conditions, this drug was unable to counteract 
Figure 4. Effect of immunodepletion of phenylalanine assemblies. HeLa cell line (A) or primary neuronal 
cells (B) were incubated with 20 mM Phe solutions for 24 or 72 h, respectively, after immunoprecipitation 
of Phe assemblies with anti-Phe antibody (anti-Phe Ab 1:10) or after immunodepletion using Sepharose-
Protein A beads (SpA). Cell viability was determined using the MTT or MTS assay. Values are 
mean ± standard deviation of 9 samples obtained in 3 different experiments. ***p < 0.001 vs Phe (20 mM). 
One-way ANOVA followed by Dunnett’s multiple comparisons test.
Figure 5. Toxicity of phenylalanine assemblies in SH-SY5Y and HeLa cell lines. Phe assembly toxicity 
was determined via MTT assay after 24 h of incubation in human neuroblastoma SH-SY5Y (A) and human 
adenocarcinoma HeLa (B) cell lines. Values are mean ± standard deviation of 9 samples obtained in 3 
different experiments. **p < 0.01, ***p < 0.001 vs control. One-way ANOVA followed by Dunnett’s multiple 
comparisons test.
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Phe assemblies toxicity (data not shown). The cell viability after treatment with 100 μ M Doxy alone was 
unaffected in both cell lines (SH-SY5Y: Doxy 96 ± 15.8%; HeLa Doxy 106 ± 16.9%).
Inhibition of phenylalanine hydroxylase activity by alpha methyl phenylamine. Effect of 
doxycycline. The chemically induced model of hyperphenylalaninemia is an alternative experimental 
approach for mimicking the pathological condition of Phe accumulation. To carry out this study we also 
used a HepG2 cell line of hepatic origin that is known to express phenylalanine hydroxylase activity. 
All three cell lines treated with 0.6 mM α -methyl-Phe for 24 h showed a significant reduction in cell 
viability to 76 ± 5.0%, 81 ± 4.5% and 81 ± 4.2% in SH-SY5Y (A), HeLa (B) and HepG2 (C) cell lines. 
Co-treatment with 25 μ M Doxy had a differential protective effect on all three cell lines, increasing cell 
viability (SH-SY5Y: 85 ± 1.0%, HeLa: 98 ± 5.5%, HepG2 118 ± 1.0, Fig. 7).
Neurotoxicity of phenylalanine assemblies. The effect of Phe on neuron and glia viability was 
investigated in mixed neuron/glia and purified neuron cultures obtained from different brain areas. 
After six days, cultures were treated for 72 h with different concentrations of Phe (from 0.12 to 60 mM). 
Dose-response curves carried out on mixed neuron/glia cultures showed that distinct brain areas have 
different sensitivity to Phe toxicity, with the hippocampus in particular showing higher vulnerability 
(EC50: 14.26 mM) than cerebellar (19.78 mM) or cortical (24.12 mM) cultures (Fig. 8A–C, solid lines). 
Phe significantly reduced neuron viability by 0.12 mM in hippocampal (80.3 ± 11.5%, p < 0.001 vs CTR) 
and cortical cultures (89.2 ± 8.6%, p < 0.05 vs CTR), but not in cerebellar cultures. The lowest Phe effec-
tive concentration in the latter was 12 mM, which reduced cell viability to 53.8 ± 11.2% (p < 0.001 vs 
CTR). Treatment with alanine (up to 20 mM) did not affect neuron/glia viability in any type of culture 
(data not shown).
To investigate the cell-specific effects of Phe, purified cell cultures (neurons or glia) were used. A 
dose-dependent toxicity of Phe was shown for purified neurons, with higher sensitivity for cortical 
(EC50: 14.42 mM) and cerebellar (27.34 mM) neurons compared to hippocampal neurons (73.58 mM; 
Fig. 8A–C, dotted lines). Interestingly, purified neurons from the hippocampus showed a lower vulner-
ability to Phe treatment as compared to mixed neuron/glia cultures from the same brain area (p < 0.05, 
Paired t-test for the dose-response curves). In fact, Phe only induced significant reduction in purified 
hippocampal neuron viability from 60 mM (57.8 ± 23.8%, p < 0.001 vs CTR; Fig. 8A).
For glial cells, microglia (EC50: 27.93 mM) were more sensitive than astrocytes (84.25 mM) to Phe 
cytotoxicity (Fig. 8D). A significant decrease in cell viability was observed at doses as low as 12 mM Phe, 
both in microglia (78.1 ± 8%, p < 0.001) and in astrocyte cultures (95.8 ± 3.1%, p < 0.05 vs CTR).
The cell death mediated by phenylalanine assemblies is counteracted by doxycy-
cline. Co-treatments with Doxy were performed in mixed neuron/glia cultures to investigate whether 
Doxy was able to prevent Phe-induced neuron death. When mixed cultures were co-treated with 25 μ M 
Doxy, the 20 mM Phe-dependent reduction of cell viability was significantly counteracted in hippocampal 
(from 51.3 ± 14.8% to 75.9 ± 11.9%; p < 0.001), cerebellar (from 56.7 ± 20.7% to 70.4 ± 7%; p < 0.05) and 
cortical cultures (from 59.8 ± 19.5% to 70 ± 10.4%; p < 0.05; Fig. 9A–C). A protective effect of Doxy was 
also observed for the cell toxicity induced by 1.2 mM Phe, although this was only seen in the hippocam-
pal cultures (p < 0.001; Fig. 9A), probably due to the higher Phe toxicity observed in these cultures.
Figure 6. Effect of doxycycline on phenylalanine assemblies toxicity. SH-SY5Y (A) and HeLa (B) cell 
lines were treated with 20 mM of Phe alone or after co-incubation with 25–50–100 μ M of Doxy for 24 h. 
Cell viability was assessed by MTT assay. Values are mean ± SD of 12 samples from 4 different experiments. 
**p < 0.01, ***p < 0.001 vs Phe alone. One-way ANOVA followed by Dunnett’s multiple comparisons test.
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Prevention of phenylalanine assemblies dependent dendritic sprouting alterations and syn-
aptic protein impairments by doxycycline. The effects of Phe (1.2–20 mM) on dendritic arbori-
sation and synaptic protein expression were analysed in a hippocampal “sandwich” neuron/glia model. 
After 10 days, co-cultures were treated for 72 h and immunostained for mature neuronal filament mark-
ers (NF200) and the presynaptic protein synaptophysin. Dendrite outgrowth evaluation and semiquan-
tification of the synaptophysin signal were performed on 3D reconstructed neuritis for each different 
treatment condition.
A significant decrease in the number of dendritic branches and Sholl intersections (specific analysis 
for branching complexity) was induced by Phe compared to the control condition by about 40–55% 
(**p < 0.01 and ***p < 0.001 versus control for 1.2 or 20 mM Phe, respectively; Fig. 10A,B). Co-treatments 
with 25 μ M Doxy partially prevented the 20 mM Phe-induced alterations in dendrite outgrowth (p < 0.05; 
Fig. 11A,B). The density of synaptophysin-positive spots was significantly increased by 20 mM Phe treat-
ment (*p < 0.05 versus control; Fig. 11 A and representative images in 11 B). Co-treatment with 25 μ M 
Doxy showed a trend to reduce the synaptic alteration induced by Phe towards control levels.
Discussion
An early study5 indicated for the first time the presence of amyloid-like assemblies in the brains of trans-
genic mouse models and patients with PKU. The co-localization of typical hallmarks of amyloid-type 
structures and the presence of Phe (Congo red staining and anti-Phe immunostaining) was used as an 
indication that self-assembled structures of Phe could accumulate in the brain and potentially cause neu-
rological illness. As a proof of Phe assemblies toxicity, the specificity and efficacy of the corresponding 
antibodies was established via immune-gold electron microscopy and the reduction of their cytotoxicity 
in Chinese hamster ovary cell lines.
On the other hand, the supramolecular organization of Phe has been observed and studied by X-ray 
crystallography7, following the claimed role of aromatic interaction in building ordered configurations 
and providing energetic contribution to the molecular assembly of peptides in amyloid structures9. In 
fact, Phe assemblies have been found to assume a supramolecular strand-like structure21 where adjacent 
layers disposition is seemingly stabilized by parallel-displaced π -π interactions between the aromatic 
moieties. Edge-to-face π stacking interactions are found between the layers and hydrogen bonds between 
carboxylate and amino groups, stabilizing the non-covalent interactions7.
The aim of our study was to explore the molecular basis of PKU, using a novel approach addressing 
the role of Phe aggregates. In this perspective, the effect of an interfering molecule – Doxy – on both 
Phe aggregation and Phe cytotoxicity was also examined, possibly helping in the development of future 
therapies, and aiding in the investigation of other metabolic diseases. We carried out small angle, wide 
angle X-ray scattering (SAXS and WAXS) and AFM experiments to obtain structural information on the 
supramolecular organization of Phe and how it is affected by the presence of Doxy. Results were con-
sistent with the presence of well-structured, aligned fibres in the pure Phe system. The presence of Doxy 
affects the local structure of Phe aggregates, significantly preventing the formation of well-ordered crys-
talline structures at very low molar ratios. In particular, the early disappearance of lateral organization, 
while preserving the Phe-piling structure, suggests a role of Doxy in interfering with inter-string H-bond 
interactions. Both fiber elongation and thickening would be prevented by induced structural fragility.
AFM observation of Phe assemblies, with and without Doxy, revealed that their morphology is sim-
ilar in solvents mimicking the X-ray diffraction and cellular models studies, namely ddH2O and 10 mM 
PBS, respectively. In both solvents, the presence of Doxy caused a significant reduction in the size of the 
assemblies. Similar experiments were also carried out at different pH (10 mM acetate buffer, pH 4.7 and 
Figure 7. Inhibition of phenylalanine hydroxylase by alpha methyl phenethylamine. Effect of 
doxycycline. SH-SY5Y(A), HeLa (B) and HepG2 (C) cell lines were incubated with 0.6 mM of α -methyl-
Phe alone or after co-incubation with 25 μ M of Doxy for 24 h. Cell viability was assessed by MTT assay. 
Values are mean ± standard deviation of 9 samples from 3 different experiments. *p < 0.05, **p < 0.01, 
***p < 0.001 vs α -methyl-Phe alone. One-way ANOVA followed by Dunnett’s multiple comparisons test.
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10 mM TRIS-HCl buffer, pH 9.2). In fact, both the Phe local structure22 and Doxy ionization state are 
pH sensitive. Our results showed that the ability of Doxy to hinder Phe assemblies spans from acidic to 
basic pH23.
The present study confirms that Phe at high concentrations forms molecular assemblies that are rec-
ognized by a specific antibody which counteracts the associated toxicity. In light of these observations, 
we tested the efficacy of Doxy on the toxicity of Phe assemblies in immortalized cell lines and primary 
neuronal cultures. The main outcome of our observations is that primary and immortalized cell lines 
of neuronal origin are more susceptible to Phe assembly toxicity than non-neuronal ones. This also 
holds true for the protective effect displayed by Doxy, which only completely counteracted Phe toxicity 
in non-neuronal cell lines. This may shed light on the selective cognitive deficit associated with PKU. 
We also carried out a series of experiments aimed at inhibiting PAH activity in three cell lines; to this 
end, we also took into account the HepG2 cell line which is of hepatic origin and possesses particularly 
high levels of PAH. In our opinion, this represents proof of concept for the potential efficacy of Doxy in 
animal models of PKU.
It has been demonstrated in human and animal brains that the hippocampus and cortex are the 
areas most involved in PKU5,24,25, characterized by progressive neuronal loss, white matter abnormalities, 
Figure 8. Phenylalanine effects on primary neuron cultures. Purified or mixed neuron/glia cultures were 
obtained from different CNS areas of mouse embryos (E13), and treated with Phe (from 0.12 up to 60 mM) 
for 72 h. (A–C) Solid lines—Phe dose-response curve in mixed neuron/glia cultures. Phe EC50 (CI95): 
14.26 mM (11.24–18.1) in hippocampal cultures; 19.78 mM (16.47–23.75) in cerebellar cultures; 24.12 mM 
(20.56–28.30) in cortical cultures. Dotted lines—Phe dose-response curve in purified neuron cultures. Phe 
EC50: 73.58 mM (47.85–113.1) in hippocampal cultures; 27.34 mM (18.09–41.3) in cerebellar cultures; 
14.42 mM (9.39–22.13) in cortical neuron cultures. (D) Solid line—Phe dose-response curve in purified 
astrocyte cultures. Phe EC50: 84.25 mM (75.84–93.60). Dotted line—Phe dose-response curve in purified 
microglia cultures. Phe EC50: 27.93 mM (23.66–32.96). *p < 0.05, **p < 0.01, ***p < 0.001 versus control. 
One-way ANOVA and Dunnett’s post-test. #p < 0.05 mixed neuron/glia cultures vs purified neuron cultures. 
Paired t-test.
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dendritic retraction or failure of arborisation and reduced synaptic density26,27. All these neuropatholog-
ical effects may be secondary to the accumulation of high concentrations of Phe28.
In our experimental conditions, Phe assemblies were toxic to neuronal cultures. In mixed neuronal/
glia co-cultures that recapitulate the complexity of brain parenchyma, the hippocampus and cerebral 
cortex both have a similar susceptibility to Phe assemblies, while in the absence of glia only purified 
cortical neurons showed a similar vulnerability. This suggests a possible contribution of glia cells to 
Phe-mediated neurotoxicity.
This was also confirmed in the co-treatment with Doxy. Hyppocampal mixed cultures were most 
responsive to Phe toxicity and to reversion by Doxy, whereas cortical and cerebellar mixed cultures 
were less influenced by the effect of Doxy. The toxicity of Phe assemblies was also evaluated by the 
analysis of dendritic sprouting and synaptophysin expression in hippocampal culture. The impairment 
in arborisation and branched projections was evident after treatment with Phe assemblies. This effect 
was sustained by a concomitant increase in expression of synaptophysin. These neuronal alterations were 
partially counteracted by co-treatment with Doxy, confirming that protection was evident only in the 
presence of high concentrations of Phe, which induce the self-aggregation phenomenon.
In conclusion, the study performed is the paradigm of an innovative repositioning approach of a well 
known antibiotic for the management of neurological diseases. In an applied perspective, the work is 
characterized by all the advantages associated with drug repositioning over drug development. One such 
advantage is represented by the availability of information on the pharmacokinetics and toxicity profiles 
of the pharmacological agent to be tested. Indeed, this type of information is a prerequisite for any 
clinical study and it minimizes safety issues, accelerating the process of testing the therapeutic efficacy 
of the selected drug for the new indication. Drug repositioning strategies are likely to boost the role of 
non-profit and academic institutions in the development of novel therapeutic approaches, as the process 
Figure 9. Doxycycline reduces phenylalanine toxicity in neuron/glia cultures. Mixed neuron/glia cultures 
from different CNS areas were exposed to 1.2–20 mM Phe alone or in co-treatment with 25 μ M Doxy, for 
72 h. Protective effects by Doxy were shown in cultures from the hippocampus, where both 1.2 and 20 mM 
Phe toxicity were significantly counteracted (A). A significant decrease in the cell death induced by 20 mM 
Phe was also observed in cortical (B) and cerebellar (C) cultures. **p < 0.01, ***p < 0.001 versus control. 
°p < 0.05, °°°p < 0.001 vs Phe. F (DFn, DFd) interaction: hippocampal cultures F (2, 200) = 17.15, p < 0.001; 
cerebellar cultures F (2, 89) = 0.7708, p = 0.4657; cortical cell cultures F (2, 171) = 0.5546, p = 0.5753. Two-
way ANOVA and Bonferroni’s post-test.
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is foreseen to result in a significant reduction of associated costs. Finally, drug repositioning is likely to be 
of particular importance for rare diseases, as it can be envisaged to fill the gap between needs and costs29.
Methods
X-ray scattering (SAXS and WAXS). Twenty mM Phe solutions were prepared in doubly distilled 
(ddH2O) together with solutions at Phe:Doxy = 1:0.005 and Phe:Doxy = 1:0.05 molar ratios. Samples were 
allowed to dry on a thin Kapton support in the presence of a 7T magnetic field. Small angle (SAXS) and 
wide angle (WAXS) X-ray scattering experiments were performed at the ID02 beamline at the European 
Synchrotron Radiation Facility (ESRF, Grenoble), with an incident X-ray wavelength λ = 0.1 nm. Spectra 
were collected in both the SAXS and WAXS configurations, in a wide region of momentum transfer, q 
(0.02 nm−1 ≤ q  ≤ 35 nm−1), to allow for structure determination on different lengthscales. The exposure 
time for each measurement was 0.2 s to avoid any radiation damage. Collected images were processed 
Figure 10. Phenylalanine-induced dendritic sprouting alterations in hippocampal neurons prevented by 
doxycycline co-treatment. Hippocampal “sandwich” co-cultures were treated with Phe/Doxy for 72 h. The 
neuron fractions were stained with NF200 and nuclei were marked by Hoechst 33258. At least eight fields 
(600x) for each condition from three independent experiments were analysed. The number of dendritic 
branches (A) and Sholl intersections (B) was significantly decreased by Phe treatments. Treatment with 
25 μ M Doxy significantly counteracted the dendritic alterations induced by 20 mM Phe. *p < 0.05, **p < 0.01, 
***p < 0.001 versus control. °p < 0.05 vs 20 mM Phe. One-way ANOVA and Tukey’s post-test.
Figure 11. Synaptophysin density alterations in phenylalanine-treated hippocampal neurons. 
Hippocampal “sandwich” co-cultures were treated with Phe/Doxy for 72 h. Cells were double-stained with 
NF200 (red) and synaptophysin (green); nuclei were marked by Hoechst 33258 (blue). The number of 
synaptophysin-positive spots was normalized to the total volume of neurofilaments (NF200 expression) 
after three-dimensional reconstruction of the marker signals (represenative images in (B). At least ten 
fields (1200x) for each condition from three independent experiments were analyzed. (A) The density of 
synaptophysin-positive spots was significantly increased by 20 mM Phe (*p < 0.05 versus control; One-way 
ANOVA and Dunnett’s post-test). Treatment with 25 μ M Doxy showed a trend towards a reduction in 
synaptophysin density, increasing towards control levels.
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and corrected using the standard ID02 software. The X-ray scattering spectra of the empty cells were 
measured in both configurations and subtracted.
Atomic force microscopy. Phe samples were dissolved at 1mM in ddH2O (pH 5.5) or in PBS 
(10 mM, pH 7.4), or in acetate buffer 10 mM (pH 4.7) or in TRIS-HCl buffer 10 mM (pH 9.2), with or 
without Doxy at 1:0.005 molar ratio, and 50 μ L were spotted onto a freshly cleaved Muscovite mica disk 
and incubated for 1 min. The disk was then washed with ddH2O, dried under a gentle nitrogen stream 
and put into a vacuum dryer for 48 h.
Samples were mounted onto a Multimode AFM with a NanoScope V system (Veeco/Digital 
Instruments) operating in Tapping Mode using standard antimony(n)-doped Si probes (T: 3.5–4.5 mm, 
L: 115–135 mm, W: 30–40 mm, f0: 313–370 kHz, k: 20–80 N/m) (Bruker).
Samples were analyzed with the Scanning Probe Image Processor (SPIP Version 5.1.6 (released April 
13, 2011) data analysis package. SPIP software was used to analyse the distribution of the molecular 
assemblies of the different populations in terms of height and diameter or height profiles, as previously 
described30.
Antibody preparation and immunoprecipitation. Antibodies were prepared by PRIMM srl 
(Milano, Italy) according to the experimental protocol approved by the Italian Ministry of Health 
(Decree number 171/2002-A, Law number 116/1992). Anti-Phe assembly antibodies were prepared as 
already described by Adler-Abramovich5 (2012) with modifications. Briefly, Phe solutions (120 mM in 
ddH2O) were kept for 24 h at room temperature until organized assemblies were formed. Rabbits were 
immunized with Phe assemblies in Freund’s adjuvant solution 7 times subcutaneously at 0 time, after 
21 days and then weekly. Two days after the last injection, the animals were sacrificed and the serum 
obtained was passed on Sepharose-Protein A (GE Healthcare). Purified immunoglobulins, at 1:10 dilu-
tion were incubated overnight at 4 °C with Phe (20 mM) in culture medium to immunoprecipitate Phe 
assemblies. Moreover, to achieve the complete elimination from the culture medium of the immune 
complex formed by Phe and the anti-Phe antibody, Sepharose-Protein A beads were added to a distinct 
batch and kept for 1 h at 4 °C. After centrifugation at 16000 x g for 10 min, the supernatant fraction was 
collected and used for cell treatment.
Culture and treatment of cell lines. Human neuroblastoma SH-SY5Y, human adenocarcinoma 
HeLa and human hepatocarcinoma HepG2 cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM Lonza) supplemented with L-glutamine (5 mM, Gibco), antibiotics (penicillin/streptomycin 
10000 U, Lonza) and 10% heat-inactivated foetal calf serum (Gibco) at 37 °C and 5% CO2 in a humid-
ified atmosphere. Cell lines were seeded (104/100 μ L) in 96 well plates and incubated overnight. After 
attachment, the medium was replaced with Phe (Sigma Aldrich) dissolved and diluted in DMEM with 
lower FCS (1%) to reduce cell growth. Alanine was used as a negative control (Sigma Aldrich). For the 
study of the efficacy of Doxy (Sigma Aldrich) on Phe toxicity or the inhibition of phenylalanine hydrox-
ylase (PAH) by α -methyl-Phe (Bachem), Doxy was freshly dissolved in ddH2O and immediately mixed 
with Phe or the inhibitor, respectively.
In all experiments cells were treated for 24 h and then their viability was determined by MTT assay. 
Tetrazolium solution (20 μ L of 5 mg/mL, Sigma Aldrich) was added to each well and incubated for 4 h. 
The medium was replaced with acidified isopropanol (0.04 M HCl) to dissolve the purple precipitate 
and the absorbance intensity was measured at 570 nm, using a plate reader (Infinite M200, Tecan). Cell 
viability was calculated as percent of control group (untreated 100%) and expressed as mean ± standard 
deviation of 3 wells for each experiment, replicated three or four times. Gentamicin (Gibco) was used as 
a negative control for antibiotic activity without effect on aggregation and fibrillation.
Primary neuronal cultures. Procedures involving animals and their care were conducted in con-
formity with the institutional guidelines at the IRCCS Istituto di Ricerche Farmacologiche “Mario Negri” 
(Quality management System Certificate—UNI EN ISO 9001:2008–Reg. N.8576-A), in compliance with 
national (D.lgs. 26/2014; Authorization n. 19/2008-A issued March 6, 2008 by Ministry of Health) and 
international laws and policies (EEC Council Directive 2010/63/UE; US NIH Guide for care and use of 
laboratory animals, 2011). The preparation of primary neurons from mice was done according to exper-
imental protocols that have been reviewed and approved by the Mario Negri Institute Research Animal 
Care and Use Committee, project number: 7/03-C, issued on May 2013, according to the Italian Law 
number 116/1992.
Primary cultures were obtained from the hippocampus, cerebellum and cortex of 13-day-old (E13) 
C57BL/6J mouse embryos as previously reported31. Tissues of interest were dissected and disrupted 
mechanically (by vigorous pipetting) and enzymatically (exposure to DNAse and trypsin; Sigma Aldrich), 
before being centrifuged through a BSA cushion. Cells obtained at this step include mixed neuron/glia 
population.
Hippocampal, cerebellar, and cortical neuron cultures. Cells obtained from the hippocampus, cerebel-
lum or cortex were plated at a density of 300,000 cells/cm2 into 96-well plates, previously pre-coated 
with poly-L-lysine (Sigma Aldrich), and maintained in complete culture medium (CCM) containing: 
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Neurobasal, 2% B27, 2% horse serum (Life Technologies), 0.5 mM L-glutamine, 25 μ M 2-mercaptoethanol, 
1% antibiotics (penicillin/streptomycin; Sigma Aldrich), and 10 ng/mL BDNF (Amgen). Glutamate 
(25 μ M; Sigma Aldrich) was added to the cultures until the 4th day in vitro (div). To obtain purified 
neurons, mixed cultures were treated with 5 μ M cytosine arabinoside (Sigma Aldrich) on the second 
div for 24 h to inhibit the proliferation of glial cells and subsequently maintained in serumless medium.
Glial cultures. Glia-enriched cultures were obtained from the cerebral cortices by plating the different 
cell populations at a density of 25,000 cells/cm2 into flasks (pre-coated with poly-L-lysine). Spared neu-
rons were eliminated using culture medium deprived of neurotrophic factors. Culture medium included: 
DMEM/F-12 (Sigma Aldrich) plus 10% heat-inactivated foetal bovine serum (Euroclone) and 1% pen-
icillin/streptomycin. Purified microglia were obtained by shaking flasks with confluent mixed glial cul-
tures overnight at 275 rpm. Floating cells (mostly microglia) were collected and seeded at a density of 
200,000 cells/cm2 into 96-well plates for neurotoxicity analysis or on a confluent astrocyte layer (approx-
imately 10% of the astrocyte number) for hippocampal “sandwich” co-cultures. Astrocyte-enriched cul-
tures were obtained by treating the glial cultures, from which microglia had been previously harvested, 
with 60 mM L-leucine methyl ester (to selectively remove microglia; Sigma Aldrich) for 90 minutes. To 
prepare a feeder layer for “sandwich” co-cultures, astrocytes were collected and seeded at a density of 
25,000 cells/cm2 into 12-well plates. For the toxicity analysis, purified astrocytes were seeded at a density 
of 200,000 cells/cm2 into 96-well plates.
Hippocampal “sandwich” co-cultures. Low-density purified neurons with healthy morphology and good 
differentiation were obtained by establishing neuron/glia co-cultures in which the two cell types were 
not in contact but shared a common medium (CCM), as previously reported31. The hippocampal cell 
suspension obtained from the dissociation of embryo brain tissues was plated at a density of 20,000 
cells/cm2 on glass coverslips with paraffin dots and maintained in serumless medium. On the second 
div, coverslips with cultured neuron were transferred into 12-well plates containing the astrocyte feeder 
layer. The coverslips were inverted so the paraffin dots created a narrow gap that prevented the contact 
of the two cell types; however, they shared a common medium. The day before treatment, microglia were 
added (5,000 cells/cm2) to the cultures.
Culture Treatments. The different cell cultures were exposed to Phe (diluted to the appropriate con-
centrations, 0.12–60 mM) in culture medium. Cultures maintained with normal medium represented 
the control condition and alanine solutions were used as negative controls. Cell viability and neuronal 
alterations were assessed after incubation for 72 h. The effects of Doxy were evaluated after co-treatment 
with Phe.
Immunocytochemistry. After treatments, cells were fixed with 4% paraformaldehyde and perme-
abilised by 0.2% Triton X-100 (Sigma Aldrich). Staining was carried out by overnight incubation with 
the primary antibodies, followed by the use of appropriate fluorescent secondary antibodies (Dy-light; 
Rockland Immunochemicals). Cell nuclei were labelled with Hoechst 33258 (Sigma Aldrich) after an 
incubation with 250 ng/mL solution. Primary antibodies were anti-neurofilament 200 (NF200, rabbit, 
1:500; Sigma Aldrich) and anti-synaptophysin (mouse, 1:500; Santa Cruz Biotechnology). Fluorescent 
secondary antibodies conjugated to different fluorochromes were used at 1:1,000 dilution (goat anti-rabbit 
tagged with 549 fluorescent dye and donkey anti-mouse tagged with 488 fluorescent dye respectively to 
recognize NF200 and synaptophysin; Rockland Inc.).
Cell viability and neuronal alterations assessment. For cell viability assessment, purified hip-
pocampal, cerebellar or cortical neurons, glial cells (microglia or astrocytes) or mixed neuron/glia cul-
tures were treated at the 3rd div for 72 h. Cell viability was assessed by evaluating the metabolic activity 
with the CellTiter96 non-radioactive cell proliferation assay (MTS test, Promega) following the manu-
facturer’s instructions.
Neurotoxic alterations (synaptic protein expression and dendritic arborisation) were analysed after 
immunocytochemistry in hippocampal “sandwich” co-cultures treated at the 10th div for 72 h as reported 
in Mariani et al.31 (2015). Z-stack pictures of stained cells were acquired at 600x or 1200x magnifi-
cation with a laser scanning microscope (Olympus Fluoview BX61 with a FV500 confocal system). 
Deconvolution, 3D reconstructions and data analysis were performed with the Imaris v7.2 software 
(Bitplane Inc.). The dendritic arborisations were evaluated via automated Sholl analysis and count of den-
dritic branches for each NF200-stained neuron. For synaptic analysis, data were expressed as the density 
of synaptophysin-positive spots normalized on the total volume of neurofilament (revealed with NF200).
Statistical analysis. In the experiments with cellular lines, data were expressed as the mean with 
standard deviation and were compared via one-way ANOVA, followed by the appropriate post hoc test 
(GraphPad Prism). Statistical significances are reported in the figure legends. In the experiments with 
primary cultures, data were analysed using Student’s t-test, one-way ANOVA and the Dunnett’s or Tukey’s 
tests, or two-way ANOVA and the Bonferroni post-test, using GraphPad v6.01 (GraphPad Software Inc.). 
The limit of statistical significance was set at p < 0.05. The EC50 (effect concentration 50, concentration 
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inducing 50% cell mortality) were calculated using GraphPad Prism software (logarithmic transforma-
tion of X-values and nonlinear regression, sigmoidal dose-response analysis with variable slope, with 
bottom and top constrains set at 0 and 100, respectively). Values are given at ± 95% confidence intervals.
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